Article

A Novel Combination of Bevacizumab and Pembrolizumab Stimulates Tumour Immunity Through Vascular Normalisation in Humanised Mouse Model

2021-01-25

Abstract excerpt

<h4>Background: </h4> Immunotherapy has dramatically changed the treatment landscape of cancer. Immunotherapies targeting the programmed death 1/programmed death ligand 1 pathway have been shown to lead to durable responses in patients with a variety of cancers. However, combination approaches are required to extend this benefit beyond a subset of patients. Studies have suggested that anti-angiogenic therapy can e...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: b567a5ef-10a4-577e-940e-dc6c8dd94234
DOI: 10.21203/rs.3.rs-152456/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A Novel Combination of Bevacizumab and Pembrolizumab Stimulates Tumour Immunity Through Vascular Normalisation in Humanised Mouse ModelDOI 10.21203/rs.3.rs-152456/v1Read

The Role of the Tumor Vasculature in the Host Immune Response: Implications for Therapeutic Strategies Targeting the Tumor MicroenvironmentSemantic proximity Read

Oncogenes and angiogenesis: a way to personalize anti-angiogenic therapy?Semantic proximity Read

Recent advances in research on multistage tumorigenesis.Semantic proximity Read

Vascularized patient-derived tumoroids supplemented with immune cells to predict response towards treatment for lung cancer patientsSemantic proximity Read

Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatmentSemantic proximity Read

Bevacizumab Reduces S100A9-Positive MDSCs Linked to Intracranial Control in Patients with EGFR-Mutant Lung Adenocarcinoma.Semantic proximity Read

Vascular targeting of LIGHT normalizes blood vessels in primary brain cancer and induces intratumoural high endothelial venules.Semantic proximity Read

Platelet-activating factor receptor (PAF-R)-dependent pathways control tumour growth and tumour response to chemotherapy.Semantic proximity Read

Switching of vascular phenotypes within a murine breast cancer model induced by angiopoietin-2.Semantic proximity Read

Anti-VEGF vascular remodeling drives germinal center B cell-rich tertiary lymphoid structures during antibody-toxin and anti-CD40 combination therapy in glioblastomaSemantic proximity Read

Bevacizumab improves the antitumor efficacy of adoptive cytokine-induced killer cells therapy in non-small cell lung cancer models.Semantic proximity Read

Combined blockade of VEGF, Angiopoietin-2, and PD1 reprograms glioblastoma endothelial cells into quasi-antigen-presenting cellsSemantic proximity Read